OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
Axel Dignaß(Goethe University Frankfurt), Jessica R. Allegretti(Brigham and Women's Hospital), William J. Sandborn(University of San Diego), Kuo‐How Huang(National Taiwan University), H Zhang(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Julián Panés(Hospital Clínic de Barcelona), Brian G. Feagan(Western University), David T. Rubin(University of California System), Brian Bressler(University of British Columbia), Nicole Shipitofsky(Janssen (United States)), Gary R. Lichtenstein(University of Pennsylvania), Matthew Germinaro(Johnson & Johnson (United States)), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 17
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k